Muscle Spasticity Market Report 2024

The muscle spasticity market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.19 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to several factors, increased investments in research and development, expansion of clinical indications, favorable regulatory approvals and reimbursement policies, a growing emphasis on adopting a multimodal approach, and a rising prevalence of multiple sclerosis.

The muscle spasticity market size is expected to see strong growth in the next few years. It will grow to $5.89 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth during the forecast period can be attributed to several factors, a growing focus on patient-centric care, expansion of distribution channels, efforts to improve quality of life, development of targeted drug delivery systems, and the discovery of biomarkers. Key trends expected to shape the market include the adoption of value-based reimbursement models, integration of artificial intelligence and machine learning technologies, use of telehealth and remote monitoring technologies, advances in neurostimulation techniques, and the application of regenerative medicine approaches.

The increasing prevalence of musculoskeletal disorders is expected to boost the growth of the muscle spasticity market. Musculoskeletal disorders affect the muscles, bones, and joints, often leading to pain, stiffness, and restricted movement. Factors contributing to the rise in these disorders include aging populations, sedentary lifestyles, and a higher incidence of chronic conditions. Muscle spasticity treatments aim to reduce pain, enhance mobility, prevent complications, and improve the overall quality of life and functional abilities of patients. For example, a study published by The Lancet in November 2023 estimated that 494 million people worldwide experienced musculoskeletal disorders in 2020, with a projected increase of 115% by 2050. Additionally, Amgen reported in May 2022 that fractures due to osteoporosis are expected to rise by 68%, from 1.9 million in 2018 to 3.2 million by 2040. This growing prevalence of musculoskeletal disorders is driving the muscle spasticity market.

Key players in the muscle spasticity market are focusing on developing oral suspensions to treat muscle spasms caused by conditions such as multiple sclerosis and spinal cord injuries. Oral suspensions are liquid medications with active ingredients dispersed for oral consumption. For instance, ANI Pharmaceuticals, a US-based pharmaceutical company, introduced baclofen oral suspension in April 2024. This product, a generic version of Fleqsuvy, is designed to treat muscle spasms by helping to relax the muscles in conditions such as multiple sclerosis and spinal cord injuries.

In January 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical manufacturer, acquired the baclofen franchise from Saol Therapeutics, including products such as Lioresal and Lyvispah. This $83.5 million acquisition aims to strengthen Amneal Pharmaceuticals' neurology portfolio and enhance its presence in the institutional market. It also supports Amneal’s entry into the biosimilar market, with expected revenue growth from the baclofen franchise by 2025. Saol Therapeutics is a US-based company specializing in developing treatments for limb spasticity and pain related to knee osteoarthritis.

Major companies operating in the muscle spasticity market are F. Hoffmann-La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Beximco Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Revance Therapeutics Inc., Acorda Therapeutics Inc., Mylan N.V., Camber Pharmaceuticals Inc., Saol Therapeutics Inc., Zydus Cadila.

North America was the largest region in the muscle spasticity market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle spasticity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Muscle spasticity is a condition marked by an abnormal increase in muscle tone or stiffness that can disrupt movement and speech. It typically arises from damage to the brain or spinal cord that affects the control of voluntary muscle movements.

The main types of drugs used to treat muscle spasticity include baclofen, botulinum toxin, diazepam, dantrolene sodium, and others. These drugs can be administered via various routes, such as oral and intramuscular. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The muscle spasticity market research report is one of a series of new reports that provides muscle spasticity market statistics, including the muscle spasticity industry global market size, regional shares, competitors with muscle spasticity market share, detailed muscle spasticity market segments, market trends, and opportunities, and any further data you may need to thrive in the muscle spasticity industry. These muscle spasticity market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The muscle spasticity market consists of revenues earned by entities by providing services such as pharmaceutical treatments, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle spasticity market also includes sales of tizanidine, gabapentin, and pregabalin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.